Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine

Harvard Medical School

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States of America

Professor of Medicine, Harvard Medical School
Thoracic Oncology, Massachusetts General Hospital
Boston, Massachusetts

Explore Activities by Rebecca S. Heist

Title
Format
Credit Type
Credits
Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2

Content Format:

Video

Credit Type:

AMA

Credits:

1.50
A Year in Review: ADCs Targeting HER2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Current Considerations for Adverse Event Management With HER3-Directed Agents

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Content Format:

Slideset

Credit Type:

--

Credits:

--
Exploring the Clinical Landscape of Novel HER3-Targeted Treatments for Advanced NSCLC

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Exploring the Clinical Landscape of Novel HER3-Targeted Treatments for Advanced NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Content Format:

Slideset

Credit Type:

--

Credits:

--
Managing the Toxicities of TROP-2 Antibody‒Drug Conjugates in Lung Cancer

Content Format:

Video

Credit Type:

--

Credits:

--
Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Content Format:

Video

Credit Type:

AMA

Credits:

1.75
Managing the Toxicities of TROP2 Antibody–Drug Conjugates in Lung Cancer

Content Format:

PDF

Credit Type:

--

Credits:

--
An Overview of ADCs: Key Structural Features and Potential Adverse Events

Content Format:

Slideset

Credit Type:

--

Credits:

--
Evolution of TROP2-Targeted ADCs in Solid Tumors

Content Format:

Slideset

Credit Type:

--

Credits:

--
HER3 as a Target for ADCs: Rationale and Clinical Evidence

Content Format:

Slideset

Credit Type:

--

Credits:

--